Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Cibus, Inc. is a pre-revenue agricultural biotechnology company developing gene-edited crop traits using its proprietary RTDS (Rapid Trait Development System) platform. The company focuses on developing herbicide-tolerant and productivity traits for major row crops including canola, rice, and soybeans, targeting commercial partnerships with seed companies rather than direct farmer sales. With negative operating cash flow of $100M annually and a market cap of $200M, the stock trades on pipeline progress and partnership announcements rather than financial fundamentals.
Cibus operates a capital-light R&D model, developing gene-edited crop traits in-house and licensing them to established seed companies (e.g., BASF, Bayer) who handle commercialization, regulatory approval, and farmer distribution. Revenue will eventually derive from per-acre royalties (typically $3-8/acre for trait stacks) once traits achieve regulatory approval and commercial launch. The RTDS platform claims faster development cycles (3-5 years vs 10+ for traditional GMOs) and regulatory advantages since gene editing avoids transgenic classification in many jurisdictions. Pricing power depends on agronomic value delivered (yield improvement, herbicide cost savings) and competitive trait availability. Current 100% gross margin reflects zero COGS on minimal licensing revenue.
Regulatory approval milestones for lead traits (e.g., USDA non-regulated status, Canadian CFIA approval for canola herbicide tolerance)
Strategic partnership announcements with major seed companies including upfront payments, milestone structures, and royalty terms
Field trial data demonstrating agronomic performance (yield advantages, herbicide efficacy, farmer adoption rates)
Capital raises and cash runway visibility - with $100M annual burn, equity dilution events drive 20-40% volatility
Competitive gene-editing developments from Corteva, Bayer, or CRISPR-focused startups that validate or threaten market positioning
Regulatory uncertainty: Gene-edited crops face evolving regulatory frameworks globally. EU classification of gene editing as GMO (requiring full transgenic approval process) would eliminate 30% of addressable market and extend time-to-revenue by 5+ years. China and India regulatory stances remain unclear.
Technological obsolescence: CRISPR-based competitors (Pairwise, Inari) claim superior precision and trait stacking capabilities. If next-generation editing platforms demonstrate meaningfully better performance, Cibus's RTDS platform could become non-competitive, stranding $200M+ in sunk R&D costs.
Farmer adoption risk: Gene-edited traits require 3-5 year adoption curves even post-approval. If agronomic benefits don't justify $5-8/acre premiums vs conventional seeds, royalty revenue will undershoot projections by 50-70%.
Incumbent seed companies (Corteva, Bayer, Syngenta) developing in-house gene editing capabilities may bypass external licensing, eliminating Cibus's partnership pathway and forcing direct-to-farmer model requiring $500M+ in commercialization capital
Patent landscape fragmentation: Broad CRISPR patents held by Broad Institute and UC Berkeley create licensing complexity. If Cibus faces patent infringement claims or must pay royalties to CRISPR patent holders, gross margins could compress from 100% to 60-70%
Cash runway crisis: With $100M annual burn and $200M market cap, the company likely has 12-18 months of liquidity. Equity raises at current valuation would be 30-50% dilutive, and any financing delays could force asset sales or bankruptcy
Debt covenant risk: 0.67 D/E ratio suggests $50-70M in debt. If covenants include cash balance or milestone achievement triggers, failure to hit regulatory timelines could trigger technical default and forced restructuring
moderate - Agricultural input spending (seeds, traits) shows 3-5 year lag to commodity price cycles. When corn/soy/canola prices are elevated, farmers invest in premium traits; during downturns, they revert to cheaper conventional seeds. However, as a pre-revenue company, Cibus is more sensitive to biotech funding cycles and risk appetite than end-market agricultural economics. VC/growth equity availability drives valuation more than farmer purchasing power until commercialization.
High sensitivity through multiple channels: (1) Pre-revenue biotech valuations compress significantly in rising rate environments as distant cash flows are discounted more heavily - 100-200bp rate increases historically correlate with 30-50% biotech index drawdowns. (2) Cost of capital for future equity raises increases, forcing greater dilution. (3) Strategic acquirer appetite declines as large ag-chem companies face higher financing costs for M&A. The company's negative $100M operating cash flow makes it entirely dependent on capital markets access.
Minimal direct credit exposure given no commercial revenue and limited accounts receivable. However, partnership counterparty risk exists: if seed company partners face financial stress, they may delay milestone payments or reduce trait commercialization investments. The 0.67 debt/equity ratio suggests some debt financing, creating refinancing risk if credit markets tighten before revenue inflection.
growth/speculative - Attracts biotech-focused venture investors and retail momentum traders betting on binary regulatory catalysts and partnership announcements. The 181% 3-month return and 131% 6-month return indicate heavy speculative positioning around near-term milestones. Not suitable for value or income investors given negative earnings, no dividends, and 5+ year path to profitability. Institutional ownership likely concentrated in specialized biotech/ag-tech funds rather than generalist portfolios.
high - Pre-revenue biotech with binary catalysts exhibits 60-100% annualized volatility. Single regulatory decisions or partnership announcements drive 30-50% single-day moves. The 181% 3-month surge followed by sector-wide biotech drawdowns typifies boom-bust pattern. Implied volatility likely trades 80-120% on any listed options, reflecting event-driven risk profile and thin float liquidity.
